Dr David Cutter
Contact information
David Cutter
FRCR, DPhil
Clinical Research Fellow (CTSU) and Consultant Clinical Oncologist (Oxford Cancer Centre)
David Cutter studied medicine at the University of Cambridge (1994-2000) and trained in Oncology at the Oxford Cancer Centre. In 2008 he joined CTSU to study for a DPhil on the late cardiovascular effects of cancer treatments. In 2013 he was appointed as a Consultant Clinical Oncologist and continues to work within CTSU upon a programme of work investigating the benefits and risks of cancer treatments.
Recent publications
-
Individualised Estimation of Quality-adjusted Survival Benefit and Cost-effectiveness of Proton Beam Therapy in Intermediate-stage Hodgkin Lymphoma.
Journal article
Jones DA. et al, (2023), Clin Oncol (R Coll Radiol)
-
Predicted cardiac and second cancer risks for patients undergoing VMAT for mediastinal Hodgkin lymphoma.
Journal article
Houlihan OA. et al, (2022), Clin Transl Oncol
-
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).
Journal article
Lyon AR. et al, (2022), Eur Heart J Cardiovasc Imaging
-
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).
Journal article
Lyon AR. et al, (2022), Eur Heart J
-
Guideline for the first-line management of Classical Hodgkin Lymphoma - A British Society for Haematology guideline.
Journal article
Follows GA. et al, (2022), Br J Haematol, 197, 558 - 572